8-K: UroGen Q3 2025: ZUSDURI Gains Momentum, JELMYTO Grows

UroGen Pharma reported its Q3 2025 financial results, highlighting accelerating ZUSDURI launch momentum and solid JELMYTO revenue growth, alongside pipeline updates and a strategic discontinuation.

Summary

• UroGen Pharma Ltd. announced financial results for the third quarter ended September 30, 2025.
• ZUSDURI (mitomycin) for intravesical solution achieved net product revenue of $1.8 million in Q3 2025, with a preliminary demand revenue estimate of $4.5 million for October 2025, indicating accelerating growth.
• ZUSDURI received a unique J-Code (J9282) in October 2025, effective January 1, 2026, and is broadly accessible with over 95% open access for covered lives.
• JELMYTO (mitomycin) for pyelocalyceal solution generated net product revenue of $25.7 million in Q3 2025, representing 13% year-over-year underlying demand revenue growth.
• The company reported $127.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• The Phase 3 UTOPIA trial for investigational drug UGN-103 (mitomycin) reported a three-month complete response rate of 77.8%, consistent with ENVISION results, and the FDA agreed to a regulatory plan for NDA submission based on this data.
• UroGen anticipates submitting an NDA for UGN-103 in the second half of 2026, with potential approval in 2027.
• Development of UGN-301 (zalifrelimab) was discontinued following completion of its Phase 1 dose escalation study, as its clinical profile did not meet internal benchmarks for advancement.
• IND-enabling studies are ongoing for UGN-501, with a goal of submitting an IND and initiating a Phase 1 trial in 2026.
• Total revenues for Q3 2025 were $27.5 million, with a gross profit of $24.2 million.
• Research and development (R&D) expenses increased to $14.0 million in Q3 2025 from $11.4 million in Q3 2024, primarily due to UGN-103 trial costs.
• Selling, general and administrative (SG&A) expenses increased to $37.6 million in Q3 2025 from $28.9 million in Q3 2024, primarily due to ZUSDURI commercial launch activities.
• Net loss for Q3 2025 was $33.3 million, or ($0.69) per basic and diluted share, compared to a net loss of $23.7 million, or ($0.51) per share, in Q3 2024.
• Full-year 2025 JELMYTO revenue guidance remains unchanged at $94 to $98 million, implying 8% to 12% year-over-year growth.
• Full-year 2025 operating expenses guidance remains unchanged at $215 to $225 million.

Sentiment

Score: 6

Explanation: The sentiment is mixed. Positives include accelerating commercial momentum for ZUSDURI, strong JELMYTO revenue growth, and promising clinical/regulatory progress for UGN-103. However, these are offset by a significantly widened net loss, substantial cash burn, and increased operating expenses. The discontinuation of UGN-301, while a strategic pipeline decision, adds a note of caution regarding R&D efficiency.

Positives

• ZUSDURI launch is gaining momentum, with October 2025 preliminary demand revenue estimated at $4.5 million, demonstrating accelerating commercial uptake from Q3's $1.8 million.
• ZUSDURI received a unique, permanent J-code (J9282) effective January 1, 2026, which is expected to facilitate reimbursement and patient access.
• ZUSDURI is broadly accessible to patients through Commercial, Medicare, and Medicaid insurance programs, with open access for more than 95% of covered lives.
• JELMYTO generated net product revenue of $25.7 million in Q3 2025, reflecting strong 13% year-over-year underlying demand revenue growth.
• The Phase 3 UTOPIA trial for UGN-103 reported a strong three-month complete response rate of 77.8%, consistent with previous clinical trial results.
• The FDA agreed with the regulatory plan to submit an NDA for UGN-103 based on data from the single-arm Phase 3 UTOPIA trial, streamlining the path to potential approval.
• The company maintains a strong financial position with $127.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• The RTGel technology platform demonstrated proof of concept for local delivery of complex immunotherapies, reinforcing its versatility and potential for future pipeline candidates.

Negatives

• Net loss widened significantly to $33.3 million ($0.69 per share) in Q3 2025, compared to $23.7 million ($0.51 per share) in Q3 2024.
• Cash, cash equivalents, and marketable securities decreased from $241.7 million at December 31, 2024, to $127.4 million at September 30, 2025, indicating a substantial cash burn.
• Total shareholders' deficit increased from $(8.803) million at December 31, 2024, to $(115.408) million at September 30, 2025.
• R&D expenses increased by $2.6 million to $14.0 million in Q3 2025, primarily driven by costs associated with the Phase 3 UTOPIA trial.
• SG&A expenses increased by $8.7 million to $37.6 million in Q3 2025, primarily due to ZUSDURI commercial launch activities and overall commercial operation costs.
• New patient starts for ZUSDURI were slower than anticipated, despite encouraging patient demand reflected in enrollment forms.
• The company made a strategic decision to discontinue the development of UGN-301 (zalifrelimab) as its overall clinical profile did not meet internal benchmarks for advancement to Phase 2.

Risks

• Clinical results may not be indicative of results that may be observed in the future, including in larger populations.
• Potential safety and other complications related to UroGen's products.
• Risks related to the company's and its licensors' ability to protect their respective patents and other intellectual property, including that pending patent applications may not be successful.
• The ability to maintain regulatory approval for products.
• Complications associated with commercialization activities.
• Labeling limitations for approved products.
• Competition in UroGen's industry.
• The scope, progress, and expansion of developing and commercializing UroGen's products and product candidates.
• The size and growth of the market(s) for products and product candidates and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures.
• UroGen's ability to attract or retain key management, members of the board of directors, and other personnel.
• RTGel technology and ZUSDURI may not perform as expected.
• New data relating to ZUSDURI, including from spontaneous adverse event reports and from the ongoing ENVISION trial, may result in changes to the product label and may adversely affect sales, or result in withdrawal of ZUSDURI from the market.
• The potential for payors to delay, limit, or deny coverage for ZUSDURI.
• The data from the UTOPIA trial may not be sufficient to support approval of UGN-103.
• UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology.
• The impacts of general macroeconomic and geopolitical conditions on UroGen's business and financial position.

Future Outlook

UroGen anticipates submitting an NDA for UGN-103 in the second half of 2026, with potential approval in 2027. The company aims to submit an IND and initiate a Phase 1 trial for UGN-501 in 2026. Full-year 2025 JELMYTO net product revenues are expected to be between $94 million and $98 million, representing 8% to 12% year-over-year growth, and full-year operating expenses are projected to be in the range of $215 million to $225 million. Next-generation medicines like UGN-103 and UGN-104 are expected to enhance supply, improve manufacturing efficiencies, and provide lifecycle extension opportunities.

Management Comments

• "Our launch of ZUSDURI, the first and only FDA-approved medicine for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, continues to gain momentum."
• "Despite slower than anticipated new patient starts, we are encouraged by the patient demand reflected in our patient enrollment forms."
• "Strong enthusiasm and engagement from urologists, growing physician awareness, and broad reimbursement coverage are expanding patient access."
• "Early launch indicators reflect robust interest and confidence in ZUSDURIs clinical value, reinforcing our belief in the significant commercial opportunity ahead and our ability to fully capitalize on it."
• "The strong complete-response rate for UGN-103 and the FDAs agreement with our NDA submission plan supports our strategy for the next-generation medicines that are expected to enhance supply, improve manufacturing and preparation efficiencies and provide opportunity for lifecycle extensions."
• "With a strong financial position, we are committed to driving a successful launch of ZUSDURI and advancing our pipeline in ways that deliver lasting impact for patients and long-term value for shareholders."

Industry Context

UroGen Pharma operates in the specialized biotech sector, focusing on innovative treatments for urothelial and specialty cancers, leveraging its proprietary RTGel sustained-release hydrogel technology. The successful commercialization of ZUSDURI and JELMYTO positions the company as a key player in bladder and upper tract urothelial cancer treatment. The discontinuation of UGN-301 highlights the inherent risks and rigorous decision-making required in drug development, while the promising clinical data for UGN-103 and the advancement of UGN-501 demonstrate continued pipeline efforts to address unmet needs in oncology. Securing a J-code for ZUSDURI is a critical step for market penetration and reimbursement in the U.S. healthcare landscape, reflecting standard industry practice for new therapies.

Stakeholder Impact

• Shareholders: Mixed impact. Positive commercial and pipeline developments offer future growth potential, but increased net losses and significant cash burn raise concerns about profitability and potential future dilution. The discontinuation of UGN-301 removes a speculative asset but also reduces associated R&D costs.
• Patients: Positive impact due to the broad accessibility of ZUSDURI and the promising clinical progress of UGN-103, which could lead to improved treatment options for urothelial cancers.
• Healthcare Providers: Positive impact with the availability of ZUSDURI and the upcoming J-code, which simplifies reimbursement, potentially increasing adoption and patient access to innovative treatments.
• Creditors: The company's existing long-term debt and prepaid forward obligation are noted. While cash reserves are still substantial, the increased net loss and cash burn warrant monitoring of the company's financial health.

Next Steps

• The ZUSDURI J-code (J9282) is expected to become effective on January 1, 2026.
• UroGen anticipates submitting an NDA for UGN-103 in the second half of 2026.
• Potential FDA approval for UGN-103 is anticipated in 2027.
• The Phase 3 clinical trial for UGN-104 is ongoing.
• IND-enabling studies for UGN-501 are ongoing, with a goal of submitting an IND and initiating a Phase 1 trial in 2026.
• A conference call and webcast will be held on November 6, 2025, at 10:00 AM ET to review financial results and provide a business update.
• The termination of the License Agreement with Agenus Inc. for UGN-301 will become effective upon the later of the expiration of the 180-day notice period or completion of all required wind-down activities.

Key Dates

Recommendation

While UroGen demonstrates promising commercial momentum with ZUSDURI and positive clinical progress for UGN-103, the significant increase in net loss and substantial cash burn are notable concerns. The discontinuation of UGN-301, though a prudent pipeline management decision, underscores the inherent risks in biotech R&D. The company maintains a strong cash position for now, but continued high operating expenses and widening losses will require close monitoring. Investors should hold to observe ZUSDURI's sustained commercial uptake and the advancement of UGN-103 towards regulatory submission and approval, balancing the commercial potential against the financial burn rate.

Keywords

UroGen Pharma, URGN, ZUSDURI, JELMYTO, UGN-103, UGN-104, UGN-301, UGN-501, RTGel, mitomycin, bladder cancer, urothelial cancer, LG-IR-NMIBC, LG-UTUC, oncology, biotech, pharmaceutical, Q3 2025, financial results, SEC filing, 8-K, clinical trial, FDA approval, NDA, J-code, commercial launch, R&D, SG&A, net loss, cash